$ERAS has been mentioned 12 times over the past 12 months by 2 distinct FinTwit voices, with the first mention appearing on 2025-11-19. The biotech-focused voices discussing Erasca are @jacobplieth (9 mentions) and @adamfeuerstein (3 mentions), with the most recent discussion on 2026-06-01. Activity around $ERAS has centered on clinical data updates and competitive dynamics within the Ras-targeted therapeutic space.

Recent mentions have focused on pan-Ras program developments and patent-related correspondence. On 2026-04-27, @adamfeuerstein noted that "$ERAS pan-Ras data update this afternoon after market close. also, $RVMD sent Erasca a letter claiming ERAS-0015 violates certain RevMed patents." Two days later on 2026-04-29, @jacobplieth commented on competitive positioning, stating "Looks like $ERAS was taking lessons from $AZN $DSNKY." Most recently on 2026-06-01, @jacobplieth referenced $ERAS in the context of conference news, posting "$ERAS is again the way to trade positive $RVMD news? #Asco26."